Peptide therapy TikTok claims: what the science actually says

What did @cecyl101 actually say?

@cecyl101 switched from tirzepatide to retatrutide for cost reasons, going from $249 to $68 a month. She says she feels "more hungry" on retatrutide and that "the food noise is definitely not gone." She's taking 5 milligrams and wonders if she's dosing it wrong, adding that she thought retatrutide was "supposed to be higher dosage or like more stronger than tirzepatide."

This is a genuinely interesting question buried in some confused terminology. She's comparing two different GLP-1 receptor agonist compounds, asking why one seems to work better for her than the other, and trying to self-adjust. That last part is where things get medically complicated fast.

Does the science back this up?

Retatrutide is not simply a stronger version of tirzepatide, and the framing of "more milligrams equals more effect" is not how these drugs work. Retatrutide is a triple agonist targeting GLP-1, GIP, and glucagon receptors, while tirzepatide targets GLP-1 and GIP only. In a Phase 2 trial (Jastreboff et al., 2023, NEJM), retatrutide at the highest doses produced mean weight loss of around 17.5% at 24 weeks, which outpaced tirzepatide data from comparable timeframes. That sounds like "stronger," but the comparison is not apples to apples.

The glucagon receptor component in retatrutide increases energy expenditure but can also complicate appetite suppression in some individuals. Individual receptor sensitivity varies. The assumption that a higher-potency drug on a population level will feel more effective for every individual is a common error. There is no published data directly comparing subjective appetite suppression experiences between these two compounds head-to-head in clinical trials.

What did they get wrong (or right)?

She is right that retatrutide showed stronger average weight loss outcomes in Phase 2 trials than tirzepatide data from the SURMOUNT program (Frías et al., 2023, Lancet). That much checks out. So the "stronger" framing has some population-level basis.

What she gets wrong is the implied logic: that more milligrams of retatrutide should reliably suppress hunger more than tirzepatide did for her personally. Dose-response curves are drug-specific. Five milligrams of retatrutide does not map onto any equivalent milligram amount of tirzepatide. These are different molecules with different receptor profiles and different titration schedules used in trials. Self-adjusting dose based on a "peptide calculator" without clinical oversight is not a safe or validated method. The titration protocol in the Jastreboff 2023 trial started at 0.5 mg and escalated slowly over weeks specifically to manage tolerability.

She is also sourcing a compounded product. Compounded retatrutide is not FDA-approved and has no regulatory equivalency to any brand-name drug. That distinction matters for both safety and predictable efficacy.

What should you actually know?

Individual response to GLP-1-based therapies varies considerably. Factors including gut receptor density, baseline metabolic rate, and prior exposure to similar compounds can all affect how well a drug suppresses appetite for a given person. The fact that she responded well to tirzepatide does not guarantee a similar or better response to retatrutide, even if trial data shows retatrutide producing greater average weight loss at population scale.

The cost difference she describes, $249 versus $68, almost certainly reflects the difference between a licensed compounding pharmacy product and another compounded product, neither of which are FDA-approved formulations. Quality, concentration accuracy, and sterility standards differ between compounding pharmacies and are not standardized. If hunger suppression feels different between two compounded products from different sources, the variable could be the product itself, not the drug's pharmacology.

Anyone adjusting peptide doses based on online calculators without a prescribing clinician involved is taking on real risk. Dose escalation decisions for this class of compound should involve monitoring for side effects including nausea, heart rate changes, and gastrointestinal distress. That is not a calculator problem to solve alone.

The bottom line

@cecyl101 is asking a legitimate question and her frustration is understandable. The science does support that retatrutide showed stronger weight loss in trials, so the "stronger" intuition has a basis. But individual pharmacological response does not follow population averages, and comparing doses across different molecules using a calculator is not medically sound. The bigger concern is that she is adjusting an unregulated compounded injectable without clinical guidance. That is the real issue here, not which drug is theoretically more potent.